



revolutionizing sample processing



Exhibit and poster presentations at CYTO conference in Denver promoting AcouSorts superior sample preparation solutions



Evaluation kit sold to European Dx collaboration partner for continued integration testing



Exhibit and partnering at BIO conference together with the EIC

Q2

INTERIM REPORT
JANUARY 1 – JUNE 30, 2025
ACOUSORT AB (PUBL)

Summary of the interim report

SIGNIFICANT EVENTS DURING THE SECOND QUARTER

- On April 1, AcouSort announced a continuation of the lease agreement of an AcouWash system to a global pharma company. To finalize the evaluations, the partnering company has decided to prolong the evaluation with another six months.
- On April 9, AcouSort published a bulletin from the extraordinary general meeting held on April 9.
- On May 6, AcouSort announced the final outcome of the rights issue of shares, which was announced on March 6. The rights issue was subscribed to a total of approximately 73 percent. Through the Rights Issue, AcouSort receives approximately MSEK 24.9 before issuing costs.
- On May 21, AcouSort announced a second order from a Central European company that develops diagnostic systems and medical devices. The company evaluates AcouSort's technology for separation of cells in body fluids.
- On June 13, AcouSort announced its CEO Dr. Torsten Freltoft was invited to participate in a panel discussion titled *Digital, wireless, smart: Integrated care in the clinic* at the international trade fair BIO 2025 in Boston, MA, June 16-19. AcouSort was one of 15 companies selected by the European Innovation Council (EIC) for participation in the European Pavilion at BIO 2025.

SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD

- On July, 28, AcouSort announced that the prestigious US National Institute of Health / National Cancer Institute has published a new article in Scientific Reports on developing processes for radiolabeling using AcouSort's AcouWash technology.

FINANCIAL SUMMARY

The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.

April - June 2025 for the Group

- Net sales amounted to TSEK 1,551 (961)
- Result before tax amounted to TSEK -2,809 (-4,714)
- Result per share* was SEK -0.14 (-0.32)
- Equity ratio** amounted to 81% (61%) on June 30, 2025

January - June 2025 for the Group

- Net sales amounted to TSEK 3,146 (2,318)
- Result before tax amounted to TSEK -6,831 (-8,443)
- Result per share* was SEK -0.41 (-0.57)
- Equity ratio** amounted to 81% (61%) on June 30, 2025

April - June 2025 for the Parent company

- Net sales amounted to TSEK 1,524 (960)
- Result before tax amounted to TSEK -2,738 (-4,326)
- Result per share* was SEK -0.14 (-0.29)
- Equity ratio** amounted to 83% (68%) on June 30, 2025

January - June 2025 for the Parent company

- Net sales amounted to TSEK 3,094 (2,318)
- Result before tax amounted to TSEK -6,653 (-7,415)
- Result per share* was SEK -0.40 (-0.50)
- Equity ratio** amounted to 83% (68%) on June 30, 2025

* Earnings/loss per share: Profit/loss for the period divided by 18,083,250 shares. In the year-earlier period, the company had 14,934,140 shares.

** Equity ratio: Equity divided by total capital.

NOTE TO THE READER

Amounts in brackets refer to corresponding period of the previous year.

This document is essentially a translation of the Swedish language version. In the event of any discrepancies between this translation and the original Swedish document, the latter shall be deemed correct.



AcouSort at a glance

AcouSort is an innovative medical technology company developing critical components for instrumentation used in the diagnostics, analytics, and cell therapy processing markets. AcouSort's components allow for automated refinement of biological samples such as blood or cell preparations, providing instrumentation manufacturers with a state-of-the-art ability to integrate sample processing steps that traditionally have to be performed manually.

OUR VISION & MISSION

Our vision is to improve healthcare impact and save lives across the globe by enabling more and better healthcare, faster! Our mission is to lead and drive the development and implementation of a new gold standard for automated sample preparation in clinical research, diagnostics and therapeutics. By providing solutions that radically change the way healthcare is provided today, we remove the bottlenecks for tomorrow's standard of care.

To realize our vision, AcouSort's main goals are:

- Support biomarker discovery and diagnostic assay development for critically ill patients with high sense of urgency
- Enable significant growth of the point-of-care market across healthcare sectors
- Streamline and automate cell processing to allow cell therapeutics to become broadly accessible
- Stay in the forefront of the acoustofluidics technology by continuously engaging in R&D activities

By pursuing these goals, AcouSort aims to become the leading supplier of acoustofluidic sample preparation solutions for the healthcare market.

OUR STRATEGY & BUSINESS CONCEPT

AcouSort's strategy is to use our innovative technology to revolutionize today's healthcare by providing a solution to automate and integrate sample processing steps, allowing for a new generation of medical devices to be developed. Through collaborations with leading Life Science companies our integrated technology will eliminate manual handling steps while saving time, money, and ultimately – lives.

Our commercialization strategy builds on our validated OEM business model offering sample preparation modules and solutions to providers of Life Science research instrumentation, diagnostic equipment, and therapeutic systems. Through close collaborations we develop customized solutions tailored to our partner's needs. AcouSort holds an ISO13485 certificate for the design, development, and manufacturing of components for the Medical Device industry.

To simplify evaluation of the technology, we have integrated our OEM components into user-friendly benchtop systems serving as innovation platforms for our partners. The systems are also used for sample preparation within research and assay development.

OUR TECHNOLOGY

AcouSort's core technology is acoustofluidics – a combination of sound waves (acousto) and microfluidics. Microfluidics allow for precise control of liquids while acoustics gives us the ability to move particles of different biophysical properties. By combining the two technologies, we have the unique ability to move target cell types from one liquid to another. This allows us to fractionate the different components in a blood sample, isolate extracellular vesicles or wash cells to remove contaminants, without having any physical contact with the sample. As the technology is gentle and rapid, it provides a competitive alternative to conventional processing techniques such as centrifugation or filtration. By using acoustofluidics, AcouSort can streamline sample processing for a wide range of applications – from biomarker discovery in basic research, to preparation of clinical blood samples prior to analysis, or sample purification in cell therapy manufacturing.

AcouSort's core technology builds on more than 20 years of acoustofluidic research and development headed by Thomas Laurell, professor at Lund University at the Department of Biomedical Engineering and co-founder and board member of AcouSort.

AcouSort through the years

2010 – 2016	2017	2018	2019	2020	2021	2022	2023	2024
<ul style="list-style-type: none"> • AcouSort is founded (2010) • Transformed from a project-based company to a fully functional organization (2016) 	<ul style="list-style-type: none"> • Listed at Aktietorget (now Spotlight) 	<ul style="list-style-type: none"> • Distribution and license agreement with IL/ Werfen • AcouSort Inc. founded • AcouWash launched • AcouTrap 2 launched 	<ul style="list-style-type: none"> • First systems placed in Japan and Korea 	<ul style="list-style-type: none"> • Changed trading venue to Nasdaq First North Growth Market • Received ISO13485 certification 	<ul style="list-style-type: none"> • AcouWash 2 launched • First OEM product AcouPlasmaOptical launched 	<ul style="list-style-type: none"> • Increased commercial focus targeting the cell therapy market 	<ul style="list-style-type: none"> • EUR 12.5M in EU funding for the AcouSome project • AcouTrap 3 launched • First regulatory approved system containing acoustofluidic technology 	<ul style="list-style-type: none"> • Launch of first clinical system based on AcouSort background technology

Further promising collaborations and strengthened finances

In the second quarter of this year, we continued tirelessly to strengthen our presence in the flow cytometry and cell therapy spaces, with new fruitful interactions and collaborations that will ultimately boost AcouSort. We also concluded a rights issue that gives us the financial stability to continue the business development of our innovative technology. Total income in the quarter amounted to MSEK 2.9 (2.0), of which royalty income amounted to MSEK 1.3 (0.8) and is expected to reach at least MSEK 5.25 for the full year.

MORE FRUITFUL PARTNERSHIPS ESTABLISHED

Our core strategy is to achieve commercial success by establishing close collaborations with life science companies, with the critical aim to launch long-term Original Equipment Manufacturer (OEM) partnerships around diagnostic equipment, cell therapy production systems, flow cytometry instruments, and quality control technologies. The ultimate goal is of course a product launch, but almost equally important for us is to reach the stage in the collaboration where our partners initiate what we call formal product development.

This strategy continues to develop very well, with a number of important contracts signed so far in 2025, of which the latest one came in late May when we received a second order from a Central European company that develops diagnostic systems and medical devices. The company is evaluating our technology for separation of cells in body fluids.

This is a great example of a collaboration that fits perfectly with our long-term strategy. We are excited by the first results from the evaluations and hope to share additional information about the project as the test program moves forward.

The collaboration was originally initiated in mid-autumn 2024 by an order of an evaluation kit that was delivered to the partner before Christmas. The project has now continued with an order of additional types of separation modules to continue the process of evaluating the broader feasibility of AcouSort's technology. This is an important step in building long-term collaborations with OEM potential.

In October 2024, we announced a new collaboration with a leading pharma company. Focus for the initial part of collaboration was to explore the potential of AcouWash technology in the partnering company's QC procedures, initially in an R&D setting. To date, the evaluation of the AcouWash technology has been highly successful. In April, due to successful evaluation data, our partner decided to prolong the evaluation with another six months to finalize their evaluation process. The total value of the extension of the collaboration is EUR 11,300.

Pending results of the finalization study, we will pursue extension of this important collaboration and provide the customer with a solution for long-term implementation in their process.

RIGHTS ISSUE GIVES US FINANCIAL STABILITY

To fulfil our ambitious development program and continue to seek new partnerships, we closed a partially secured rights issue on May 5. It was subscribed to a total of about 73 percent, with approximately 51 percent subscribed by underwriters.

The proceeds amounted to MSEK 24.9 before issuing costs and are intended to be used to moving current and future collaborations into fully-fledged OEM partnerships over the next 16-18 months. Together with known income, such as royalties and public funding, as well as projected product and project revenues, the rights issue is aimed at funding our business development activities at least into 2027.

In parallel, we continue to identify and discuss with different stakeholders to obtain an investor structure with a long-term vision that can take AcouSort all the way to successful and profit-



able commercialization. These activities started late 2024 and will continue undiminished in 2025. We are fully committed to further expanding the impact of AcouSort's unique technology in the Life Science sector and secure the financial support to achieve this.

BUSY PERIOD FOR BUSINESS DEVELOPMENT

The first contacts with potential partners are typically made at international conferences and trade fairs, and it is very important for us to be present at different significant international events where we have the possibility to meet new partners, as well as continue developing our relationships with existing ones.

I am pleased to say that we are well recognized in the scientific community, and a sign of this is the invitation we received to participate in a panel discussion at the international trade fair BIO 2025 in Boston, MA, in June. AcouSort was one of 15 companies selected by the European Innovation Council (EIC) for participation in the European Pavilion at BIO 2025.

The delegates were selected based on their internationalization goals, technological fit with the scope of the trade fair, as well as their capacity to create business through their participation

BIO 2025 is one of the most important conferences in the health-care and biotech industry, where most leading companies are represented and which will provide us with a great opportunity to keep extending our reach within the rapidly evolving healthcare space. In the session, titled *Digital, wireless, smart: Integrated care in the clinic*, I presented AcouSort's innovative technology and exemplified how automated sample preparation is an important cornerstone in the healthcare future.

We plan to attend several more conferences in 2025 where we can demonstrate our technology and meet companies that are working on current and next generation cell therapies where AcouSort has the potential to play a vital role. The significantly increased influx of new potential OEM projects proves that our intensified marketing efforts at conferences and trade fairs is paying off.

It is also very rewarding that our projects are being published in scientific journals. After the period, we announced that Scientific Reports, part of the Nature publishing house, had published a new article by the prestigious US National Institute of Health / National Cancer Institute (NIH/NCI) on developing processes for radiolabeling using AcouSort's AcouWash technology. We are very pleased that the NIH, which is an important reference customer, has produced additional positive results in their new study. This also verifies our strategy of using benchtop systems as platforms for developing applications of our technology.


OUTLOOK

Backed by a stable financial position, a very talented organization, and a growing network of partners, we will continue to strengthen our positions in diagnostics, cell therapy, flow cytometry and quality control. By continuing to develop existing and future partnerships over the coming year, our focus is to take AcouSort to the next exciting stage and shape the future of the company. I will keep you updated as we make progress in our projects.

Torsten Freltoft – CEO
ACOUSORT AB

STRATEGY

Growth through research and innovation collaborations



AcouSort's technology is perfectly placed to play a critical role in the healthcare of tomorrow. Cardiovascular diseases, infections, and cancer are the three deadliest diseases in the world. There is a great need for new and effective diagnostic and cell therapeutic solutions, but current sample processing and manufacturing workflows are facing significant challenges as they rely on a number of manual sample handling processes. Manual handling often entails a high risk of errors as well as bacterial contamination during the production process of cell therapeutics. This puts a high price tag on the therapy, thereby limiting the number of patients who can be offered a potentially life-saving treatment. It is clear that the industry is in great need of inventions in order to really take off.

POTENTIAL FOR SIGNIFICANT IMPROVEMENTS IN CELL THERAPY AND DIAGNOSTICS

AcouSort's ambition is to address the challenges in cell therapy by introducing solutions that enable automated sample processing and integration to limit the need for manual handling in the manufacturing workflow. Our technology fits well in several steps in the process and has a fantastic potential to lower manufacturing cost.

Within diagnostics, our unique ability to automate and integrate sample processing steps will also allow for a new generation of medical devices. Patient samples can be analyzed directly at the point-of-care instead of at central laboratories, meaning that doctors and patients get the results immediately.


GROWTH THROUGH OUR RESEARCH-TO-OEM MODEL

AcouSort's strategy focuses on our research-to-OEM model, which has the ambition to establish continuous revenues from sales of OEM modules to large Life Science companies. By establishing multiple partnerships in the cell and gene therapy and diagnostic markets, we aim to build a network of researchers and partners for joint developments to take us to a commercially matured technology. Recently, we substantially strengthened our commercial capacity, and we are currently targeting the North American market, the European market, and selected markets in Asia. Through collaborations with leading Life Science companies our technology will eliminate manual handling steps while saving time, money, and ultimately – lives.

INNOVATION WITH GREAT POTENTIAL


In 2022, AcouSort and a group of partners received a grant of SEK 26 million by the EIC to develop an acoustofluidic thin film actuated chip for exosome separation from blood. Exosomes are nanoparticles that enable human cells to communicate vital information with each other. Thereby, exosome separation has the potential to open a completely new field within diagnostics and therapies. Of the SEK 26 million, SEK 12.2 million go directly to AcouSort, and the remainder of the funding is distributed to AcouSort's partners Lund University, DTU, and DayOne. The project will run for 36 months and is fully funded by the EU.

Top three causes of deaths globally




Source: WHO

Cell & Gene Therapies Approved – World




Source: ASGCT_Citeline Q4 2022 Report

Accumulated AcouSort OEM projects and system placements



Advancement within point-of-care testing requires automation of sample preparation



To fight the deadliest diseases in the world – cardiovascular, infectious, and cancer diseases – while the world’s population in many countries is either growing or aging, faster and more efficient diagnostics are needed. One of the most important steps towards achieving this is to move diagnostic testing closer to the patient, thus being able to act immediately on the result. For most diagnostics tests, this will require integrated and automated sample processing, and AcouSort’s advanced sample preparation modules provide an optimal solution to achieve this.

Today, almost all blood tests taken in the health care system are shipped to a central hospital or other laboratory facility. There, the samples are processed, and diagnostic assays are performed. For about 75% of the blood samples processed, the sample must be centrifuged to separate the blood cells from the blood plasma that is required to perform the requested tests. To implement most of today’s blood-based diagnostic tests as point-of-care tests, the required blood-plasma separation must be seamlessly integrated into the point-of-care device. Depending on the specific diagnostic assay in question, AcouSort’s OEM separation modules – AcouWash, AcouPlasmaOptical and AcouTrap – offer optimal solutions to this challenge.

MARKET

The current trend in diagnostic testing aims to decentralize testing enabling faster and more accurate diagnostics. To provide the use of more advanced diagnostics outside of clinical laboratories, the interest in solutions for automated sample preparation is increasing. The global point-of-care testing (POCT) market size was accounted at USD 40.6 billion in 2021 and it is expected to reach around USD 103.2 billion by 2030¹ corresponding to an average annual growth of about 11%.

OFFERING

AcouSort works with providers of point-of-care diagnostic systems to customize our OEM modules to their future or next generation systems. AcouSort’s modules are designed for integration into consumable or semi-consumable cartridges that our partners design to be used in their instruments. When more and more system providers integrate our separation modules into their clinical diagnostic systems, AcouSort business model is highly scalable and with a significant revenue potential.

FOCUS 2025

In 2025, AcouSort will maintain its focus at reaching additional diagnostic customers by providing our acoustic separation modules as evaluation test kits. The evaluation kits expand the possibilities for more potential collaboration partners to evaluate the technology and to speed up the initial evaluation phases. In addition to this, the 2025 plans involve creating additional marketing materials showing the value provided by AcouPlasmaOptical when it comes to speeding up measurements of cells or plasma analytes directly in whole blood or other biofluids.

Activities 2025

Quarter 1


- Business development activities to reach new diagnostic partners in Korea by participation in EU business hub outreach.
- Initiation of collaboration with UK based company to explore feasibility of AcouSort technology to improve sepsis treatments.

Quarter 2

- Visited Euromedlab conference in Brussels to meet with developers of POC diagnostic systems.
- Production and delivery of evaluation kit to European based diagnostic company for further feasibility and integration testing of AcouSort technology.

¹ <https://www.precedenceresearch.com/point-of-care-testing-market>

Automated cell processing facilitates the cell therapy revolution



The world is facing a revolutionary increase in clinically approved cell therapies during the coming years. Unfortunately, the complex and expensive manufacturing process significantly limits the access to these treatments. All major Life Science instrumentation companies have active programs targeting automation of the cell therapy processing to manage cost and quality. AcouSort's automated cell separation and processing technology is well suited for providing new mainstream solutions for these novel cell therapies.

The number of clinically approved cell and gene therapies is rapidly increasing, with even more in the pipeline. Cell therapies can have price tags of up to USD 500,000 per treatment, a price level that is prohibitive for most health insurances or public health care plans. The reason for this currently very high cost is a combination of the need for sterile labs and the extensive manual handling required to produce the therapeutic cells.

MARKET

The global cell therapy market size was valued at USD 21.6 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 14.15% from 2023 to 2030¹, thus exceeding USD 60 billion in 2030. The market is constantly growing to include new cell therapies, which presents a significant opportunity for companies to strengthen their market positions. As a result, during the past few years, there has been a dramatic increase in the number of companies engaged in the development of cell therapies.

OFFERING

AcouSort has been approached by a handful of multinational Life Science companies seeking solutions to enclose and automate the cell therapeutics processing and eliminate the current manual processing. Our separation modules are well suited for this as they can automatically perform the cell wash, cell up-concentrations and separation of target cell types needed.

AcouSort's strategy is to develop and supply the automated cell processing modules as single use OEM components to our Life Science instrumentation partners. In this way, the AcouSort business model is both scalable and represents a significant revenue potential.

FOCUS 2025

In 2025, AcouSort will continue to develop its cell separation modules in close collaboration with customers within cell therapy. Continued focus will be on technical development to further increase the sample throughput. We've made significant progress regarding the robustness and ease of integration for the high throughput solution that can be used across several different application areas. We will now develop evaluation test kits and focus on internal application development to further strengthen our offering to OEM customers within cell therapy, stem cell isolation, and flow cytometry applications.

Activities 2025

Quarter 1


- Participated in Phacilitate Advanced Therapies Week in Dallas to network with key companies in the cell therapy field working on technologies for cell and gene therapy.
- Initiated collaboration with Bio-Recell by hosting visit in Lund to explore first proof of principle for stem cell isolation combining the companies' technologies.
- Manufactured and delivered two evaluation kits to US based cell therapy company.

Quarter 2

- Participation in BIO conference in Boston. The conference is a networking event and provided a great opportunity to meet with developers of cell therapy production equipment.
- Poster presentation at CYTO conference showing the results from our latest work on cell health. Cells processed using AcouSort's GMP-compliant workflows show superior metabolic health and proliferation, a great example of our gentle technology.

¹ From <https://www.grandviewresearch.com/industry-analysis/cell-therapy-market>

Driving the development and exploitation of automated sample processing



Through partnerships with leading universities and through our Research and Innovation platforms – AcouWash and AcouTrap – AcouSort strives to continue driving the innovation of acoustofluidics for automated sample preparation and processing. Our innovation projects are to a large extent funded through public contributions from EIC/EU and from Vinnova.

AcouSort is constantly interacting with current and potential partners and customers through meetings and active participation in scientific conferences and tradeshows. The feedback from these interactions is used to direct our Research and Innovation activities.

COMMERCIAL RESEARCH AND INNOVATION PLATFORMS

To enable the development of new or improved applications of our automated sample processing technology, we have developed two benchtop Research and Innovation platforms, the AcouWash and the AcouTrap. We provide these systems to researchers and key opinion leaders at universities and to our OEM collaboration partners in the Life Science industry. Through our academic research partners and their publications and presentations, we distribute information about our technology and its applications. And through the collaboration with the OEM partners, the systems enable access to the automated sample processing modules at a very early stage in their technical assay or system development process. The use of our Research and Innovation platforms by leading research groups contributes to broaden the application fields of the technology while promoting the use of our technology in general through their scientific publications.

THE ACOUSOME PROJECT

The AcouSome project is a fully EU funded EIC Transition project with two main commercial innovation goals. The most fundamental goal is to replace the currently glass-based and bulk piezo activated separation modules with modules made in polymer. If successful, this innovation will significantly reduce the produc-

tion price of our separation modules, paving the way for single use applications of these in point-of-care diagnostics. However, the project also has the goal of developing a robust and simple-to-use device for isolating extracellular vesicles from whole blood samples, enabling development of new diagnostic modalities.

The AcouSome project is funded 100% by the European Innovation Council (EIC) with EUR 2.5 million over 36 months (2023-2025). Our partners in this project are the Technical University of Denmark, Lund University and DayOne.

FOCUS 2025

During 2025, AcouSort will continue developing the acoustic trapping application targeting extracellular vesicles within the EU-supported AcouSome and EVEREST projects. For the AcouWash research and innovation platform, the focus will be on continuing to support ongoing evaluation projects related to sample preparation for quality control and flow cytometry applications.

AcouSort will also explore the opportunity of forming partnerships with manufacturers of spectrophotometry systems to co-develop and co-market applications where the sample preparation capability provided by the AcouPlasmaOptical enables analysis of new types of samples. Initial focus will be on the bioprocessing market, while also exploring other opportunities. Evaluation test kits will be developed expanding the possibilities for potential collaboration partners to evaluate the products and to speed up the initial evaluation phases.

Activities 2025

Quarter 1

- Customer and conference visit in Canada showcasing AcouSort's technology and exploring new research collaborations within the flow cytometry field.
- Initiation of EVEREST project where AcouSort is continuing to explore AcouTrap technology for extracellular vesicle (EV) isolation where AcouSort has supported University College Dublin with optimizing AcouTrap parameters to improve EV isolation for flow cytometry.

Quarter 2

- Participation in CYTO conference and presentation of the latest results from University of Ottawa in a joined poster presentation. The conference gave an excellent opportunity to meet with developers of flow cytometry instrumentation and showcase our solutions.
- Initiation of application development project to improve MNC separation from blood to meet increased interest from customers for this application.

Industry collaborations

Collaborations with life science companies developing diagnostic equipment, cell therapy production systems, flow cytometry instruments, and quality control technologies represent a cornerstone of AcouSort's strategic transition from research-focused activities to Original Equipment Manufacturer (OEM) integration. These partnerships are instrumental in advancing AcouSort's long-term objective of embedding its proprietary technology as integrated components within third-party medical and laboratory devices.

Initial engagements typically begin with the leasing of AcouSort's benchtop systems, the purchase of evaluation kits, or the execution of smaller-scale feasibility studies. Where a strong technological alignment is identified, these early-stage collaborations often evolve into long-term strategic partnerships.

The timeline for the early stages of these collaboration is very difficult to predict. However, the timeline for launching new products following the initiation of Formal Product Development is

more predictable, but varies across application segments. For diagnostic systems, the expected development cycle is approximately 3 to 5 years. In the cell therapy segment, we estimate the timeline to typically 1 to 3 years, while for quality control and flow cytometry applications, product launches are generally anticipated within 1 to 2 years.

Partner	Description	Concept study	Feasibility testing	Early Product development	Formal product development	Validation / beta testing	Product launch
Dx1	Werfen (Instrumentation Laboratory) License agreement, first published on June 8 2018						2024
CT1	Global life science company active in the cell therapy field, first published Nov 14 2022			●			
FC1	Leading life science company developing flow cytometers, first published on May 15 2023		●				
QC1	GenSensor, first published on April 29 2024				●		
FC2	US based company evaluating sample preparation and cell wash for cytometry-like applications, first published on April 26 2024			●			
CT3	US based cell therapy company, first published on July 29 2024			●			
QC2	Leading global pharma company evaluating AcouWash for quality control in an R&D setting, first published on October 23 2024			●			
DX2	Central European company that develops diagnostic systems, first published on May 21 2025			●			
FC 3	Leading flow cytometry instrument manufacturer, first published on August 5 2024			●			
DX 3	UK based company focused on improving sepsis treatment, first published on March 19 2025		●				
CT 4	Bio Recell, first published on March 03 2025	●					

● Active ● Pending ● On hold ● Discontinued

AcouSort's research collaborations


Sound is created when a vibration generates pressure waves that propagate through a medium. When the wave encounters a particle, the particle is moved by the acoustic forces generated by the wave. In acoustofluidics, the technology used by AcouSort, ultrasound is used to create standing acoustic waves in microfluidic channels. The standing wave typically focuses the particles

toward the pressure node, where the pressure variation is the lowest. The sound frequency is similar to diagnostic ultrasound and has been shown to be very gentle to biological samples, with no activation or decrease in viability. Acoustofluidics can be implemented in two different ways, acoustic separation, and acoustic trapping.

To stay at the forefront, AcouSort is continuously developing the acoustofluidic technology further together with universities and commercial partners.

Project	Sponsor	Goal	Partners	Duration	Status	AcouSort grant	Total project grant
AcouSome	European Innovation Council	Development of a miniaturized microfluidic module for exosome isolation directly from blood using ultrasound generated by thin films, to be used in research and diagnostics.	Lund University, DTU, DayOne	2023-2025	Ongoing	EUR 1,100,000	EUR 2,500,000
IndiCell	Vinnova	Development of a world leading innovation milieu for individualized induced pluripotent stem cell derived therapies, to lower the risks and overcome hurdles for the translation from basic science to innovations and further to clinical applications.	Lund University, Karolinska Institute, KTH, Lab-On-A-Bead AB, Skåne University Hospital, BioLamina AB, Karolinska University Hospital	2021-2026	Ongoing	EUR 110,000	EUR 3,520,000*
Blue4Therapy	Eureka, Vinnova, Innovation Fund Denmark	Development of a platform for specific stem cell isolation from autologous adipose tissue for effective regenerative therapy, together with universities and commercial partners.	Blue Cell Therapeutics, University of Southern Denmark, Novozymes A/S	2020-2023	Completed April 2023	EUR 300,000	EUR 800,000
AcouPlast	Eureka, Vinnova, Innovation Fund Denmark	Development of polymer chips to make acoustic separation even more cost efficient and easy to integrate into diagnostic and analytical systems.	DTU, Ortofon A/S, Lund University	2019-2023	Completed Mar 2023	EUR 400,000	EUR 1,000,000
BioWings	EU Horizon 2020	Development of thin films generating the ultrasound used for cell processing to make acoustofluidic chips more efficient and easier to manufacture.	Weizmann Institute of Science, EPFL, PIEMACS, DTU, Lund University	2018-2022	Completed Nov 2022	EUR 180,000	EUR 3,000,000

*Currency conversion from SEK, i.e. the total project grant in EUR is approximate.



AcouPlasmaOptical



AcouTrap



AcouWash

AcouSort's products

OEM COMPONENTS

AcouSort's main strategy is to develop and commercialize Original Equipment Manufacturer (OEM) components for sample preparation and processing. The OEM solutions enable integration of our technology into analytical, diagnostic, and therapeutic systems, providing automated sample preparation. The customer base for the OEM components are instrument manufacturers within the Life Science industry.

AcouSort intends to expand the portfolio of OEM components to cover a wide range of applications for clinical analysis and handling of biological samples. The Company expects the acoustic separation components to be critical components, essential for development of novel point-of-care testing devices where access to blood plasma or other fractions of blood is required. This also applies for biological sample processing systems in therapeutic settings for e.g., personalized medicine.

AcouPlasmaOptical

Integrated blood plasma separation. AcouPlasmaOptical is an OEM component designed for integration into diagnostic instruments as a semi-consumable. It enables automated and rapid access to plasma for optical measurements of blood analytes in point-of-care diagnostic devices. The technology uses gentle acoustic forces in combination with microfluidics to create a plasma window for optical access in whole blood samples without the need for prior centrifugation. Centrifugation often requires manual intervention that may have negative effects on sample quality, making AcouPlasmaOptical a competitive alternative.

Custom made solutions for interfacing of sample flow and electronic connection are available. Design, development and manufacturing of AcouPlasmaOptical is ISO13485 certified.

AcouSort offers evaluation kits to partners interested in exploring integration of the component into their systems.

RESEARCH AND INNOVATION SYSTEMS

AcouSort has developed two benchtop systems, the AcouTrap and the AcouWash, to offer the Company's core acoustofluidic techniques, i.e., trapping and separation techniques, in an easy-to-use format. The instruments serve as Research and Innovation platforms, providing easy access to the technology for instrument manufacturers interested in integrating acoustofluidic OEM components into their systems. With user-friendly hardware and software, the instruments enable automated handling of biological samples, supporting academic researchers and product development teams working with new biomarker identification and diagnostic assay development.

AcouTrap

Handling of cells and extracellular vesicles. AcouTrap is a benchtop research instrument for automated enrichment, washing and staining of biological samples. AcouTrap provides a solution for gentle and rapid sample preparation of biological particles of various sizes. The AcouTrap system is excellent for sample preparation of precious cell samples, where traditional methods are ill-suited as they can dramatically decrease recovery and viability. The AcouTrap efficiently automate common sample

preparation steps such as up-concentration, high recovery washing and labelling of low cell number samples. The system also facilitates handling of nanoparticles, including bacteria, viruses, and extracellular vesicles. These particles are very small, often less than one micrometer in size, and are found in complex biological liquids such as blood plasma. The small dimensions and the complexity of the liquid makes isolation through conventional techniques challenging. With AcouTrap, isolation is automated and manages samples with smaller volumes than the competing technologies. This enables research studies with biobank samples only provided in minute fluid volumes.

AcouWash

Automated cell separation. AcouWash is a benchtop research instrument for label-free separation of target cells from a variety of sample types. The system provides automated processing and is designed to perform sensitive separations and handle fragile cells without any impact on viability. The acoustic forces used in the AcouWash provides samples with very high quality and with minimal sample to sample variation.

With the AcouWash system, a variety of applications aimed at separation of blood cells can be automated. Common applications comprise gentle and highly efficient cell wash, label-free separation of mononuclear cells from whole blood, isolation of platelets, rare cell isolation (e.g., circulating tumor cell, CTC) as well as blood-plasma separation for diagnostic applications.

Income statement – Group

(SEK thousand)	4/1/2025 6/30/2025	4/1/2024 6/30/2024	1/1/2025 6/30/2025	1/1/2024 6/30/2024	1/1/2024 12/31/2024
Operating income					
Net sales	1,551	961	3,146	2,318	4,737
Other income	1,329	1,033	2,363	2,649	5,293
Total income	2,880	1,993	5,509	4,967	10,030
Operating expenses					
Raw materials	0	0	-51	0	34
Other external expenses	-1,989	-2,234	-3,670	-4,491	-8,787
Personnel costs	-3,335	-4,375	-7,516	-9,325	-17,169
Depreciations	-42	-60	-91	-126	-233
Other operation expenses	0	-3	0	-3	0
Total expenses	-5,366	-6,671	-11,328	-13,945	-26,155
OPERATING RESULT	-2,487	-4,678	-5,820	-8,978	-16,126
Result from financial items					
Financial income	40	0	59	571	2,320
Financial expenses	-363	-36	-1,070	-36	-1,271
Total financial items	-323	-36	-1,012	535	1,048
Result after financial items	-2,809	-4,714	-6,831	-8,443	-15,078
Result before taxes	-2,809	-4,714	-6,831	-8,443	-15,078
Tax on this year's result	-8	0	-8	0	0
Result for the period	-2,817	-4,714	-6,839	-8,443	-15,078
Result per share, SEK - before dilution	-0.14	-0.32	-0.41	-0.57	-1.01
Result per share, SEK - after dilution	-0.14	-0.31	-0.40	-0.55	-0.97


Operating results

For the second quarter of the year AcouSort Group reported net sales of TSEK 1,551 (961), which consisted of product sales of TSEK 262 (117) and licence fees of TSEK 1,289 (843). Other operating income consists of grants amounting to TSEK 1,329 (1,033).

Other external expenses amounted to TSEK -1,989 (-2,234). Personnel costs amounted to TSEK -3,335 (-4,375). Depreciation amounted to TSEK -42 (-60).

For the second quarter of the year AcouSort Group's operating result totalled TSEK -2,487 (-4,678).

Total income, SEK thousand



AcouSort has been successful in applying for public R&D grants within Sweden and the EU. Since 2021, AcouSort has been awarded SEK 19.2 million in research and development grants.

Apparently incorrect sums are explained by rounding in the rows leading to the sum.

Balance sheet – Group

ASSETS (SEK thousand)	6/30/2025	12/31/2024
Fixed assets		
<i>Intangible assets</i>		
Concessions, patents, licences, trademarks, and similar rights	4,686	4,448
Total intangible assets	4,686	4,448
<i>Tangible assets</i>		
Equipment, tools, and installations	39	85
Total tangible assets	39	85
<i>Financial assets</i>		
Other long-term receivables	12	12
Total financial assets	12	12
Total fixed assets	4,736	4,545
Current assets		
Inventories	2,509	2,525
Account receivable	241	60
Other receivables	473	370
Prepaid expenses and accrued income	1,682	1,257
Cash and cash equivalents	16,675	3,568
Total current assets	21,580	7,779
TOTAL ASSETS	26,316	12,324

Financial Position

On June 30, 2025, AcouSort Group's equity ratio was 81% (61). Equity amounted to TSEK 21,258 (15,297). Cash and cash equivalents amounted to TSEK 16,675 (16,683). Total assets for the Group amounted to TSEK 26,316 (25,043).

Apparently incorrect sums are explained by rounding in the rows leading to the sum.

EQUITY AND LIABILITIES (SEK thousand)	6/30/2025	12/31/2024
Equity		
<i>Restricted equity</i>		
Share capital	2,116	1,493
	2,116	1,493
<i>Non-restricted equity</i>		
Other contributed capital	117,328	99,116
Reserves	21	-45
Retained earnings	-91,368	-77,024
Profit/loss for the period	-6,839	-15,078
	19,141	6,969
Total equity	21,258	8,463
Current liabilities		
Account payables	961	859
Tax liabilities	79	177
Other liabilities	317	433
Accrued expenses and deferred income	3,701	2,392
Total current liabilities	5,058	3,861
TOTAL EQUITY AND LIABILITIES	26,316	12,324

Statement of changes in equity – Group

(SEK thousand)	Share capital	Other contributed capital	Reserves	Retained earnings	Loss for the period	Total
Opening balance January 1, 2024	1,490	99,278	170	-59,714	-17,089	24,135
Prior year 's result	0	0	0	-17,089	17,089	0
Conversion difference	0	0	-215	-222	0	-437
Warrants, Serie 2023/2026	0	0	0	1	0	1
Redemption Warrants 2020/2023	3	-3	0	0	0	0
Costs, rights issue	0	-158	0	0	0	-158
Loss for the period	0	0	0	0	-15,078	-15,078
Equity December 31, 2024	1,493	99,116	-45	-77,024	-15,078	8,463
Opening balance January 1, 2025	1,493	99,116	-45	-77,024	-15,078	8,463
Prior year 's result	0	0	0	-15,078	15,078	0
Conversion difference	0	0	66	734	0	800
Rights issue	623	24,296	0	0	0	24,919
Costs, rights issue	0	-6,084	0	0	0	-6,084
Loss for the period	0	0	0	0	-6,839	-6,839
Equity June 30, 2025	2,116	117,328	21	-91,368	-6,839	21,258

Apparently incorrect sums are explained by rounding in the rows leading to the sum.


Cash flow statement – Group

(SEK thousand)	4/1/2025 6/30/2025	4/1/2024 6/30/2024	1/1/2025 6/30/2025	1/1/2024 6/30/2024	1/1/2024 12/31/2024
Operating activities					
Operating result	-2,487	-4,678	-5,820	-8,978	-16,126
Depreciations	42	60	91	126	233
Financial income / expense	-323	-36	-1,012	535	1,048
Cash flow from operating activities before changes in working capital	-2,768	-4,654	-6,741	-8,316	-14,844
Change in working capital					
Increase/decrease inventories	-10	-113	16	-137	-445
Increase/decrease in receivables	-1,227	-348	-710	2,732	2,999
Increase/decrease in current liabilities	-1,844	1,657	1,196	-631	-6,517
Changes in working capital	-3,081	1,195	502	1,963	-3,963
Cash flow from operating activities	-5,849	-3,459	-6,239	-6,353	-18,807
Investing activities					
Increase/decrease of intangible assets	-178	-267	-283	-566	-1,028
Increase/decrease of financial assets	1,048	0	994	12	12
Cash flow from investing activities	870	-267	711	-554	-1,016
Financing activities					
Rights issue	24,919	0	24,919	-158	0
Costs, rights issue	-5,999	0	-6,084	0	-158
Warrants	0	0	0	1	1
Cash flow from financing activities	18,920	0	18,835	-157	-157
Change in cash and cash equivalents	13,940	-3,725	13,307	-7,064	-19,980
Cash and cash equivalents at the beginning of the period	3,448	20,377	3,568	23,986	23,986
Conversion difference and other adjustments	-712	31	-200	-239	-438
Cash and cash equivalents at the end of the period	16,675	16,683	16,675	16,683	3,568

Cash flow and investments

AcouSort Group's cash flow for the second quarter of the year was TSEK 13,940 (-3,725). Investments amounted to TSEK 870 (-267), of which TSEK -178 (-267) pertained to intangible assets and TSEK 1,048 (0) to financial assets.

Cash and cash equivalents last five quarters, SEK thousand



At the end of the second quarter, the Group had cash and cash equivalents amounting to TSEK 16,675, which allows AcouSort to continue its planned activities at least into 2027.

Apparently incorrect sums are explained by rounding in the rows leading to the sum.

Income statement – Parent company

(SEK thousand)	4/1/2025 6/30/2025	4/1/2024 6/30/2024	1/1/2025 6/30/2025	1/1/2024 6/30/2024	1/1/2024 12/31/2024
Operating income					
Net sales	1,524	960	3,094	2,318	4,760
Other income	1,329	1,033	2,363	2,649	5,293
Total income	2,854	1,993	5,457	4,967	10,053
Operating expenses					
Raw materials	0	0	-51	0	34
Other external expenses	-1,891	-2,135	-3,440	-4,303	-8,422
Personnel costs	-3,335	-4,085	-7,516	-8,486	-16,328
Depreciations	-42	-60	-91	-126	-233
Other operation expenses	0	-3	0	-3	0
Total expenses	-5,269	-6,283	-11,098	-12,918	-24,949
OPERATING RESULT	-2,415	-4,290	-5,641	-7,951	-14,896
Result from financial items					
Loss from shares in group companies	0	0	0	0	-2,000
Financial income	40	0	59	571	2,320
Financial expenses	-363	-36	-1,070	-36	-1,271
Total financial items	-322	-36	-1,012	535	-952
Result after financial items	-2,738	-4,326	-6,653	-7,415	-15,848
Result before taxes	-2,738	-4,326	-6,653	-7,415	-15,848
Tax on this year's result	0	0	0	0	0
Result for the period	-2,738	-4,326	-6,653	-7,415	-15,848

Operating results

For the second quarter of the year, the parent company reported net sales of TSEK 1,524 (960), which consisted of product sales of TSEK 235 (117) and licence fees of TSEK 1,289 (843). Other operating income consists of grants amounting to TSEK 1,329 (1,033). Other external expenses for the period amounted to TSEK -1,891 (-2,135). Personnel costs for the period amounted to TSEK -3,335 (-4,085). Depreciation for the period amounted to TSEK -42 (-60). The second quarter's operating result for the parent company totalled TSEK -2,415 (-4,290).

Apparently incorrect sums are explained by rounding in the rows leading to the sum.

Balance sheet – Parent company

ASSETS (SEK thousand)	6/30/2025	12/31/2024
Fixed assets		
<i>Intangible assets</i>		
Concessions, patents, licences, trademarks, and similar rights	4,686	4,448
Total intangible assets	4,686	4,448
<i>Tangible assets</i>		
Equipment, tools, and installations	39	85
Total tangible assets	39	85
<i>Financial assets</i>		
Shares in group companies	9	9
Receivables from group companies	3,428	4,422
Other long-term receivables	12	12
Total financial assets	3,449	4,443
Total fixed assets	8,173	8,975
Current assets		
Inventories	2,509	2,525
Account receivables	183	60
Other receivables	473	370
Prepaid expenses and accrued income	1,682	1,124
Cash and cash equivalents	16,455	3,042
Total current assets	21,302	7,121
TOTAL ASSETS	29,475	16,096

Financial Position

On June 30, 2025, the parent company's equity ratio was 83% (68). Equity amounted to TSEK 24,417 (20,668). Cash and cash equivalents amounted to TSEK 16,455 (16,288). Total assets amounted to TSEK 29,475 (30,414).

Apparently incorrect sums are explained by rounding in the rows leading to the sum.

EQUITY AND LIABILITIES (SEK thousand)	6/30/2025	12/31/2024
Equity		
<i>Restricted equity</i>		
Share capital	2,116	1,493
Development expense fund	4,686	4,448
	6,802	5,941
<i>Non-restricted equity</i>		
Share premium	117,328	99,116
Retained earnings	-93,060	-76,974
Profit/loss for the period	-6,653	-15,848
	17,615	6,294
Total equity	24,417	12,236
Current liabilities		
Account payables	961	859
Tax liabilities	79	177
Other liabilities	317	433
Accrued expenses and deferred income	3,701	2,392
Total current liabilities	5,058	3,861
TOTAL EQUITY AND LIABILITIES	29,475	16,096

Statement of changes in equity – Parent company

(SEK thousand)	Share capital	Development expense fund	Share premium	Retained earnings	Loss for the period	Total
Opening balance January 1, 2024	1,490	3,520	99,278	-62,095	-13,952	28,241
Prior year 's result	0	0	0	-13,952	13,952	0
Development expense fund	0	928	0	-928	0	0
Warrants, Serie 2023/2026	0	0	0	1	0	1
Redemption Warrants 2020/2023	3	0	-3	0	0	0
Costs, rights issue	0	0	-158	0	0	-158
Loss for the period	0	0	0	0	-15,848	-15,848
Equity December 31, 2024	1,493	4,448	99,116	-76,974	-15,848	12,236
Opening balance January 1, 2025	1,493	4,448	99,116	-76,974	-15,848	12,236
Prior year 's result	0	0	0	-15,848	15,848	0
Development expense fund	0	238	0	-238	0	0
Rights issue	623	0	24,296	0	0	24,919
Costs, rights issue	0	0	-6,084	0	0	-6,084
Loss for the period	0	0	0	0	-6,653	-6,653
Equity June 30, 2025	2,116	4,686	117,328	-93,060	-6,653	24,417

Apparently incorrect sums are explained by rounding in the rows leading to the sum.

Cash flow statement – Parent company

(SEK thousand)	4/1/2025 6/30/2025	4/1/2024 6/30/2024	1/1/2025 6/30/2025	1/1/2024 6/30/2024	1/1/2024 12/31/2024
Operating activities					
Operating result	-2,415	-4,290	-5,641	-7,951	-14,896
Depreciations	42	60	91	126	233
Financial net	-322	-36	-1,012	535	-952
Cash flow from operating activities before changes in working capital	-2,696	-4,266	-6,562	-7,289	-15,615
Change in working capital					
Increase/decrease inventories	-9	-113	16	-137	-445
Increase/decrease in receivables	-1,238	-376	-784	1,368	7,524
Increase/decrease in current liabilities	-1,845	1,657	1,197	-632	-6,517
Changes in working capital	-3,092	1,167	429	598	562
Cash flow from operating activities	-5,787	-3,099	-6,133	-6,692	-15,053
Investing activities					
Increase/decrease of intangible assets	-178	-267	-283	-566	-1,028
Increase/decrease of financial assets	293	0	994	12	-4,410
Cash flow from investing activities	116	-267	711	-554	-5,438
Financing activities					
Rights issue	24,919	0	24,919	-158	0
Costs, rights issue	-5,999	0	-6,084	1	-158
Warrants	0	0	0	0	1
Cash flow from financing activities	18,920	0	18,835	-157	-157
Change in cash and cash equivalents	13,248	-3,365	13,412	-7,402	-20,648
Cash and cash equivalents at the beginning of the period	3,206	19,653	3,042	23,690	23,690
Cash and cash equivalents at the end of the period	16,455	16,288	16,455	16,288	3,042

Cash flow and investments

The parent company's cash flow for the second quarter was TSEK 13,248 (-3,365). Investments amounted to TSEK 116 (-267), of which TSEK -178 (-267) pertained to intangible assets and TSEK 293 (0) to financial assets.

Apparently incorrect sums are explained by rounding in the rows leading to the sum.

Other information

THE SHARE

AcouSort's share was listed on Spotlight Stock Market January 9th, 2017. In December 2020 the share changed list to Nasdaq First North Growth Market, with December 14th as the first trading day. The ticker symbol of the share is "ACOU", and the ISIN-code is SE0009189608. First North Growth Market is an alternative marketplace run by NASDAQ OMX GROUP. Companies traded on First North Growth Market do not have to be compliant to the same rules as companies traded on a regulated market. Instead, the companies follow under less strict rules applied for growth companies. The risk of investing in a company traded on First North Growth Market may thus be greater than investing in a company traded on a regulated market. All companies with shares traded on First North Growth Market have a Certified Adviser that supervises the compliance of the rules. The stock exchange examines applications to be listed on the exchange. AcouSort's Certified Adviser on Nasdaq First North Growth Market is Carnegie Investment Bank AB (publ), +46 (0)73 856 42 65. As of June 30, 2025, the number of shares in AcouSort AB was 21,163,902 (14,934,140). The Company has one class of shares. Each share carries one (1) vote per share and carries equal rights to share in the Company's assets and earnings.

THE SUBSIDIARY ACOUSORT INC

AcouSort AB has a wholly owned subsidiary in the USA, AcouSort Inc. The Company's task is to carry out marketing and sales on the North American market.

BUSINESS-RELATED RISKS AND UNCERTAINTIES

In summary, the risks and uncertainties that AcouSort's operations are exposed to are related to, among other things, competition, technology development, market conditions, capital needs, currencies and interest rates. No significant changes in risk or uncertainty factors occurred during the current period. For more detailed reporting of risks and uncertainties, please refer to the Annual Report.

The group makes continuous simulations regarding expected liquidity development for the coming twelve-month period. These simulations are based on the current order backlog, ongoing EU-funded R&D projects, planned investments as well as operational costs. The Group's simulations show that the Group has sufficient liquidity for the coming twelve-month period..

In a scenario where the Group would not succeed in achieving the budgeted sales revenues, there is a potential risk the Group may experience liquidity problems. This means that liquidity development constitutes an uncertainty factor regarding the Group's continued operations. It is the Group's current assessment that such a situation can be handled without a new issue being carried out.

UPCOMING FINANCIAL REPORTS

- Q3 2025: November 26, 2025
- Q4 2025: February 25, 2026

REVIEW BY AUDITORS

The interim report has not been reviewed by the Company's auditor.

PRINCIPLES FOR THE INTERIM REPORT'S ESTABLISHMENT

The interim report has been prepared in accordance with the Swedish Accounting Standards Board's General Council 2012:1 Annual Report and Consolidated Accounts (K3) and the Annual Accounts Act.

	Jan - Jun 2025	Jan - Jun 2024	Jan - Dec 2024
Number of shares before dilution	21,163,902	14,934,140	14,934,140
Number of shares after dilution	21,715,900	15,486,138	15,486,138
Result per share before and after dillution	-0.40	-0.50	-1,06
Average number of shares before dilution	16,517,394	14,934,140	14,931,742
Average number of shares after dilution	17,069,392	15,486,138	15,483,740

Declaration by the Board of Directors and the CEO



Thomas Laurell



Stefan Scheduling



Katherine Flagg



Stefan Blomsterberg



Per Sundkvist



Torsten Freltoft

The Board of Directors and the Chief Executive Officer certify that the interim report provides a true and fair view of the Company's business, financial position, performance and describes material risks and uncertainties, to which the Company is exposed.

The report has not been reviewed by the Company's auditors.

Lund, 26 August, 2025

Thomas Laurell
Chairman

Stefan Scheduling
Board member

Katherine Flagg
Board member


Stefan Blomsterberg
Board member

Per Sundkvist
Board member

Torsten Freltoft
CEO

For further information, contact:

Torsten Freltoft, CEO
Telephone: +45 20 450 854
E-mail: torsten.freltoft@acousort.com
Website: www.acousort.com
Address: Medicon Village, SE-223 81 LUND, Sweden



AcouSort
revolutionizing sample processing